These results indicate that, for those tumors that may relapse (and for which a different genetic signature may need to be found), the joint expression of (ARF1) [37] or Breast Cancer Anti-estrogen Resistance 1 (BCAR1) [38] and Ferroportin (SLC40A1)[39]–[42] may be associated to the time to relapse. This evidence concerns the gene ARF1 and breast carcinoma.